Connect with us

Finance

Iowa State University names new VP of operations and finance • Iowa Capital Dispatch

Published

on

Iowa State University names new VP of operations and finance • Iowa Capital Dispatch

Iowa State University has named Sean Reeder as senior vice president of operations and finance after completing a separation agreement with former vice president Shawn Norman.

Reeder will start in the new role Sept. 3, pending approval from the Iowa Board of Regents, according to a news release.

He comes to the university after serving as vice chancellor for finance and administration at the University of Missouri, Kansas City for more than two years. He has also held positions at Eastern Illinois University, the University of Illinois system and Michigan State University.

GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX

Advertisement

“Dr. Reeder has the right blend of experience, knowledge and accomplishments to excel in this position,” President Wendy Wintersteen said in the release. “I and the senior leadership team look forward to working with him as we continue to build on Iowa State’s strengths and land grant mission.”

Iowa State University Senior Vice President of Operations and Finance Sean Reeder (Photo courtesy of Iowa State University)

ISU signed a separation agreement with Norman in December after less than a year of him holding the position, paying him $124,000 in a “separation payment” with Norman agreeing to cut ties with the university. Caitlynn Miller, the executive assistant to the senior vice president for operations and finance, also entered into a settlement agreement to receive the same amount of money after alleging “harassment and retaliation.”

Advertisement

David Spalding, dean of the Ivy College of Business, is currently serving as interim senior vice president of operations and finance, according to the release.

The operations and finance division oversees university units including financial planning and analysis, facilities planning and management, capital planning, the university bookstore and Reiman Gardens, among others.

“Iowa State University is an amazing example of what the land-grant research university can be,” Reeder said in the release. “President Wintersteen has laid out a bold strategic plan, and I am ready to roll up my sleeves and get to work in delivering this plan. ISU’s mission, vision and values align with my own, and I’m honored to join the Cyclone family.”

Advertisement
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Finance

Tech stocks lead Nasdaq, S&P 500 rebound: A break down

Published

on

Tech stocks lead Nasdaq, S&P 500 rebound: A break down

The Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) indexes are rebounding from downward pressures that hit tech stocks (XLK) at the beginning of August. Now, Big Tech names, particularly Nvidia (NVDA), are seeing major gains. Why are tech stocks seeing this rebound and is it time to buy back into the sector?

Yahoo Finance markets reporter Josh Schafer joins Morning Brief to break down tech’s reversal from last week’s sell-off and how the sector is leading the market rally on Friday morning.

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This post was written by Nicholas Jacobino

Continue Reading

Finance

Binance exec insists bitcoin can recover despite 20% drop | Future Focus

Published

on

Binance exec insists bitcoin can recover despite 20% drop | Future Focus

On this week’s episode of Yahoo Finance Future Focus, our host Brian McGleenon interviews Vishal Sacheendran, Binance’s Head of Regional Markets, to discuss the current state of the cryptocurrency market. Despite bitcoin being down over 20% from its all-time high of $73,000 reached in May, Sacheendran suggests that several potential bullish catalysts could drive a recovery. Sacheendran expresses confidence that the current downturn in bitcoin and the broader cryptocurrency market doesn’t signal a long-term negative trend. He points to several factors that could benefit the digital asset, including the anticipated start of a U.S. Federal Reserve rate-cutting cycle and the upcoming U.S. presidential election, where pro-crypto candidates like Donald Trump and Robert F. Kennedy Jr. are making waves. Sacheendran emphasises the increased synchronicity between traditional financial markets and the cryptocurrency market, noting the growing presence of institutional investors and the introduction of Bitcoin and Ethereum ETFs. He highlights that market sentiment is optimistic, with the CME FedWatch tool showing a significant likelihood of a rate cut in September, which could further support a rebound in the cryptocurrency market.

Continue Reading

Finance

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Published

on

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

LOS ANGELES, Aug. 15, 2024 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company“), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of life sciences accounting and finance veteran David House as Senior Vice President, Finance, effective August 16th. Armata’s Corporate Controller, Richard Rychlik, will retain the position of Controller.

“We are delighted to welcome David to the Armata team,” stated Dr. Deborah Birx, Chief Executive Officer of Armata. “David’s extensive experience and track record of serving in senior accounting and finance roles within both clinical and commercial stage life sciences companies will serve us well as we continue to advance our two distinct programs – AP-PA02 and AP-SA02 – and prepare to initiate pivotal studies next year. This is an exciting time at Armata, and the addition of David to our senior team helps ensure that we are best positioned to achieve long-term success as we work to introduce an exciting new class of anti-infectives to treat serious drug-resistant bacterial infections.”  

Before joining Armata, Mr. House served as Corporate Controller and Vice President of Accounting at ZO Skin Health, Inc., a multi-channel physician-dispensed skincare company, from October 2018 to May 2024. At ZO Skin Health, he led global accounting operations, managed financial reporting, and played a crucial role in the company’s acquisition by Blackstone. He also established international subsidiaries and oversaw financial integration for mergers and acquisitions. Mr. House’s experience includes similar financial leadership roles at Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Avid Bioservices, Inc. (CDMO), a contract development and manufacturing organization where he served as Controller and was responsible for implementing ASC 606, managing technical accounting, and conducting Securities and Exchange Commission (the “SEC“) reporting.

Mr. House’s career also includes roles at Viant, Inc. (DSP), Sourcing Solutions, LLC, and Apria Healthcare (APR), where he held various accounting and financial management positions. In the early stages of his career, Mr. House worked as a Senior Auditor at Windes, a public accounting firm. There, he managed comprehensive audits for public, private, and not-for-profit entities and contributed to SEC filings and internal control evaluations. Mr. House holds a Bachelor of Arts in Business Administration with an Accounting concentration from California State University, Fullerton. He obtained his California Certified Public Accountant license, which is currently inactive.

About Armata Pharmaceuticals, Inc.

Advertisement

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.

Forward Looking Statements

This communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant current Good Manufacturing Practices; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors” and elsewhere in Armata’s filings and reports with the SEC, including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 21, 2024, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Media Contacts:

Advertisement

At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
[email protected]
310-665-2928 x234

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
[email protected]
212-915-2569

SOURCE Armata Pharmaceuticals, Inc.

Continue Reading

Trending